Key result
Daily natural alpha interferon therapy in multiple sclerosis patients reduced in vitro leukocyte interferon synthesis to 11-44% of pretherapy values and caused a loss of priming reactivities.
Why the study?
Does daily natural alpha interferon treatment alter leukocyte interferon synthesis and responsiveness in multiple sclerosis patients?
RCT
Does daily natural alpha interferon treatment alter leukocyte interferon synthesis and responsiveness in multiple sclerosis patients?
Daily alpha interferon therapy in multiple sclerosis patients leads to decreased leukocyte interferon synthesis and loss of priming reactivity, indicating the development of cellular resistance to interferon.
Answers are grounded in this paper and cite their sources.
May indicate interferon resistance in MS; leaves open clinical impact and need for in vivo validation.
Despite the use of interferon (IFN) in numerous clinical trials, relatively little is known about how IFN therapy influences leukocyte function. To evaluate some of its effects, leukocytes from multiple sclerosis (MS) patients given daily treatments of natural alpha IFN (IFN-alpha) were evaluated for IFN synthesis and two responses to IFN in vitro: enhancement (priming) of IFN synthesis and suppression of Concanavalin A (Con A)-induced T-cell mitogenesis. The IFN therapy had no effect on the sensitivity of Con A-stimulated leukocytes to the antiproliferative action of IFN-alpha. However, using Newcastle disease virus (NDV), measles virus, or poly I:C to stimulate IFN synthesis, cells from IFN-treated patients produced less IFN in response to all inducers, with titers ranging between 11% and 44% of pretherapy values. Also, unlike cells from these same patients before therapy or from the placebo recipients, cells from the IFN recipients were not primed by either IFN-alpha or -beta even though IFN-beta had not been used for therapy. The loss of these priming reactivities suggests that resistance to IFN had developed in IFN-treated patients.
No takes yet. Share an insight, caveat, or question.
Kamin‐Lewis et al. (1984) conducted an RCT in Multiple sclerosis. Natural alpha interferon (IFN-alpha) vs. Placebo was evaluated on Interferon synthesis and responsiveness to interferon in vitro. Daily natural alpha interferon therapy in multiple sclerosis patients reduced in vitro leukocyte interferon synthesis to 11-44% of pretherapy values and caused a loss of priming reactivities.
Synapse has enriched 10 related papers. Consider them for comparative context: